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Follicular helper T (Tfh) cells are recognized as a distinct CD4+ helper T-cell subset, which provides for B-cell activation and
production of speciﬁc antibody responses, and play a critical role in the development of autoimmune disease. So far, only one
study investigated the circulating Tfh cells increased in a subset of SLE patients. Since relatively little is known about the Tfh cells
in rheumatoid arthritis (RA) patients, in this study, Tfh-cell frequency, related cytokine IL-21, and transcription factor Bcl-6 were
investigated in 53 patients with RA and 31 health controls. Firstly, we found that the frequency of CD4
+CXCR5
+ICOS
high Tfh cells
was increased signiﬁcantly in the peripheral blood of RA patients, compared with that in healthy controls. It is known that Tfh
cells are critical for directing the development of an antibody response by germinal centers B cells; secondly, we observed that the
Tfh-cell frequency is accompanied by the level of anti-CCP antibody in RA patients. Furthermore, expression of Bcl-6 mRNA and
plasma IL-21 concentrations in RA patients was increased. Taken together, these ﬁndings have shown that the increased frequency
of circulating Tfh cells is correlated with elevated levels of anti-CCP antibody, indicating the possible involvement of Tfh cells in
the disease progression of RA.
1.Introduction
Rheumatoid arthritis (RA) is a chronic and symmetric pol-
yarticular arthritis that primarily aﬀects the small diarthro-
dial joints of the hands and feet [1]. The salient features of
RA include the presence of circulating autoantibodies, dy-
sregulated lymphocyte activation, and linkage to MHC class
II [1]. Although both T cells and B cells are involved in
the disease pathogenesis, CD4+ T cells and their cytokines
are thought to play a crucial role in the induction and pro-
pagation of the inﬂammatory conditions. With the help of T
cells, activated B cells migrate into lymphoid follicles of lym-
phoid organs and form germinal centers (GCs) [2]. Within
the unique milieu of the GCs, follicular B cells undergo
somatic hypermutation and aﬃnity maturation, resulting
in the diversiﬁcation and selection of B-cell repertoire for
and diﬀerentiate into antibody-secreting plasma cells and
memory B-cell [3, 4]. Current studies have indicated a
fundamental function of CD4+ T cells in regulating B cells
proliferation and antibody production especially in the GC
structures [5].
Recently, follicular helper T (Tfh) cells, a novel CD4+
T subset, have been found to be present in GCs [6],
which regulate the development of antigen-speciﬁc B-cell
immunity in vivo [7]. Tfh cells provide selection signals to
GCs B cells and play an essential role in mediating long-lived
antibody responses. The phenotypic and functional features
of Tfh cells include surface expression of the chemokine
receptor CXCR5 [chemokine(C-X-C motif) receptor 5],
IL-21,andB-cellCLLlymphoma-6(Bcl-6)[8,9].Highlevels2 Clinical and Developmental Immunology
of CXCR5 expression facilitate the homing of Tfh cells to B-
cell follicles whereas Bcl-6 is essential for the generation of
Tfh cells and functions in a gene dose-dependent manner
[10]. It becomes clear that IL-21 produced by Tfh cells
serve as an important regulator of humoral responses by
directly regulating B-cell proliferation and class switching
[5]. However, little is currently known about the potential
role of Tfh cells in autoimmune pathogenesis.
An elegant study by Simpson et al. [11]h a sr e c e n t l y
shown that the frequency of circulating CD4+CXCR5+
ICOShigh Tfh cells was increased in SLE patients, which
promptedustoexaminethefrequencyofcirculatingTfhcells
in the peripheral blood of RA patients and its correlation
with autoantibody production. In this study, the increased
frequencyofCD4+CXCR5+ICOShigh circulatingTfhcellswas
detected in RA patients, which was positively correlated with
high levels of serum anti-CCP antibody. Thus, these results
have indicated the possible involvement of Tfh cells in the
pathogenesis of RA.
2.MaterialsandMethods
2.1. Patients. A total of 53 RA patients and 31 health
controls were enrolled in the present study. Fifty-three newly
diagnosed RA patients without treatment from 2009 to
2010 at the Aﬃliated People’s Hospital of Jiangsu University
were included in this study. RA patients fulﬁlled the 1987
revised criteria of the American College of Rheumatology
(ACR) [12]. Thirty-one healthy volunteers were recruited
as controls. Peripheral blood samples were obtained from
all patients and healthy controls. The clinical characteristics
were collected at the same time points as the plasma samples.
Data describing the study subjects are summarized in
Table 1. Ethical approval was obtained from Jiangsu Univer-
sity, and written informed consent was obtained from all
individuals.
2.2. Cell Isolation. Plasma was collected through centrifuga-
tio nandst o r edat−80◦Cformeasurementofcytokinelevels.
PBMCs were isolated by standard Ficoll-Paque Plus density-
gradient centrifugation for analysis by ﬂow cytometry. CD4+
T cells were puriﬁed from PBMCs by FITC-conjugated
anti-human CD4 mAb and anti-FITC microbeads (Miltenyi
Biotec GmbH, DE) according to the manufacturer’s instruc-
tions.
2.3. Flow Cytometric Analysis. For phenotypic analysis, ﬂu-
orescein isothiocyanate (FITC)-ICOS, phycoerythrin (PE)-
CD4, and PE-Cy5-CXCR5 monoclonal antibodies against
human-cell surface were purchased from eBioscience (San
Diego, CA, USA). All the staining was performed according
to the manufacture’s protocol. The stained cells were then
analyzedusingtheBDFACScalibursystemandCELLQUEST
software.
2.4. Real-Time Polymerase Chain Reaction. For the detection
of IL-21 mRNA of CD4+ T cells, CD4+ Tc e l l sw e r e
incubated in complete RPMI1640 culture medium in the
Table 1: Clinical features of RA patients included in the study.
RA Range
n 53
Gender(M/F) 9/44
Age(yr) 54.44 ± 14.69
RF(IU/mL) 243.66 ± 427.16 <20IU/mL
CCP-Ab(RU/mL) 256.81 ± 300.34 <25RU/mL
Data correspond to the arithmetic mean ±SD, M: Male; F: Female.
presence of 50ng/mL phorbol myristate acetate (PMA).
After 4h of culture at 37◦C under 5% CO2, the cells were
collected and centrifuged at 500g for 5min. After being
washed in phosphate-buﬀered saline (PBS), TRIzol reagent
was added. Total RNA was extracted from CD4+ Tc e l l s
with TRIzol reagent and cDNA synthesized according to
manufacurer’s instructions (Takara, Japan). Each gene was
ampliﬁed in triplicate, and cDNA concentration diﬀerences
were normalized to β-actin [13]. Primer sequences were as
follows: IL-21 sense, 5 -CACAGACTAACATGCCCTTCAT-
3 , and antisense, 5 -GAATCTTCACTTC CGTGTGTTCT-
3 ; Bcl-6 sense, 5 -AAGGCCAGTGAAGCAGAGA-3 ,a n d
antisense, 5 -CCGATAGG- CCATGATGTCT-3 .
2.5. Enzyme-Linked Immunosorbent Assay (ELISA). Level
of plasma IL-21 was done using ELISA for human IL-21
(eBioscience, San Diego, CA, USA). All determinations were
performed by duplicate, and the lower detection limits for
IL-21 were 31pg/mL. The plasma from RA patients was
tested for the presence of anticyclic citrullinated peptide
(anti-CCP) antibody by ELISA. All samples were analyzed in
duplicateusingtheaverageoftheopticaldensity(OD)values
to calculate concentrations.
2.6.StatisticalAnalysis. Datawerepresentedasmean ±stan-
dard deviation in the text and ﬁgures. Statistical diﬀerences
were considered to be signiﬁcant at a value P<0.05 as
determinedbystudent’st-testusingSPSS13.0.Correlationof
nonparametric paired data was tested using Spearman’s rho,
and the signiﬁcance was evaluated using the t statistic.
3. Results
3.1. Increased Frequency of the Circulating Tfh Cells in
RA Patients. Because the inducible costimulatory molecule
(ICOS) is a T-cell activation marker, and it has been re-
ported that the frequency of CD4+ICOS+T cells was in-
creased in RA patients. We ﬁrst analyzed the frequency of
CD4+ICOS+ and CD4+ICOShigh T cells in PBMCs from
RA patients and healthy controls by ﬂow cytometry.
Figures 1(d) and 1(e) showed that the frequencies of CD4+
ICOS+ and CD4+ICOShigh T cells in RA patients were higher
than those in healthy controls (P<0.001). CXCR5 has
enabled the Tfh cells to enter the follicles during T-cell-
dependent immune responses. In both mice and humans,Clinical and Developmental Immunology 3
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Figure 1: Increased frequency of circulating follicular helper T (Tfh) cells in peripheral blood from rheumatoid arthritis (RA) patients.
Peripheral blood mononuclear cells (PMBCs) from RA patients (n = 31) and healthy controls (n = 30) were stained with labelled antibodies
as described in Methods. (a) Representative expression of ICOS versus CD4 expression by ﬂow cytometry, values in each CD4+ gate
(ICOShigh [black box], ICOS positive [ICOS intermediate plus ICOShigh [+]], and ICOS negative). (b) Representative ﬂow cytometry plots
of Tfh (CD4+CXCR5+) cells. (c) Representative ﬂow cytometry plots of Tfh (CD4+CXCR5+ICOShigh) cells. (d) Percentage of CD4+ICOS+ T
lymphocytes in RA patients and healthy controls (∗∗∗P<0.001). (e) Percentage of CD4+ICOShigh T lymphocytes in RA patients and healthy
controls (∗∗∗P<0.001). (f) Percentage of CD4+CXCR5+ T lymphocytes in RA patients and healthy controls (∗∗P<0.01). (g) Percentage of
CD4+CXCR5+ICOShigh T lymphocytes in RA patients and healthy controls (∗∗∗P<0.001). Each data point represents an individual subject,
and horizontal lines show the median.
there have been shown that CXCR5+ and ICOShigh are
important phenotype for CD4+ Tfh cells. We use ﬂow cy-
tometry to analyze the frequency of the circulating Tfh
cells in PBMCs from RA patients and healthy controls.
A signiﬁcantly increased frequency of CD4+CXCR5+ and
CD4+CXCR5+ICOShigh circulating Tfh cells was detected
in RA patients, compared with that in healthy controls
(Figures 1(f) and 1(g)) (P<0.01 and P<0.001, resp.). Our
data indicated that increased fraction of the circulating Tfh
cells is apparent in a subset of RA patients.4 Clinical and Developmental Immunology
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Figure 2: Correlation of circulating Tfh cells frequency and autoantibody in RA patients. (a) Relationship between the frequency of
circulating Tfh cells and the positive anti-CCP antibody (r = 0.5429, P = 0.0163) (n = 19). (b) Relationship between the frequency of
circulating Tfh cells and the negative anti-CCP antibody (r =− 0.2000, P = 0.6134) (n = 6). (c) Relationship between the frequency of
circulating Tfh cells and the level of RF (r =− 0.1356, P = 0.5577) (n = 21). (d) Increased frequency of circulating Tfh cells in RA patients
according to anti-CCP antibody. Horizontal lines show the median.
3.2. High Levels of Autoantibodies and Increased Frequency of
the Circulating Tfh Cells in RA Patients. I no r d e rt oa n a l y z e
the association between autoantibody and the circulating
Tfh cells, we compared the levels of plasma autoantibodies
(anti-CCPantibodyandRF)andfrequencyofthecirculating
Tfh in RA patients. According to the titer of anti-CCP anti-
body, RA patients were divided into two groups: anti-CCP
antibody-positive group and anti-CCP antibody-negative
group. The frequency of the circulating Tfh cells showed a
positive correlation with anti-CCP antibody-positive group
in plasma (r = 0.5429, P = 0.0163, Figure 2(a))b u t
not with anti-CCP antibody-negative group (r =− 0.2000,
P = 0.6134, Figure 2(b)), whereas RF concentrations did not
show any correlation with the percentage of the circulating
Tfh cells (r =− 0.1356, P = 0.5577, Figure 2(c)). The
diﬀerence was accounted for by a 3–9-fold increase in
CD4+CXCR5+ICOShigh circulating Tfh cells in 7of the 19
RA patients between anti-CCP antibody-positive group and
anti-CCP antibody-negative group (Figure 2(d)).
3.3. Increased Bcl-6 mRNA, IL-21 mRNA Expression, and
IL-21 Concentrations in RA Patients. Previous studies
demonstrated that the Bcl-6 was a key transcription factor
for Tfh cells. We assessed the expression of transcription
factor Bcl-6 in RA patients and healthy controls. Real-
time polymerase chain reaction showed that Bcl-6 mRNAClinical and Developmental Immunology 5
0
2
4
6
8
Control Rheumatoid
arthritis
∗∗
B
c
l
-
6
 
m
R
N
A
-
r
e
l
a
t
i
v
e
 
e
x
p
r
e
s
s
i
o
n
 
(
×
1
0
3
)
(a)
Control Rheumatoid
arthritis
∗∗
0
0.2
0.4
0.6
0.8
1
I
L
-
2
1
 
m
R
N
A
-
r
e
l
a
t
i
v
e
 
e
x
p
r
e
s
s
i
o
n
 
(
×
1
0
3
)
(b)
Control Rheumatoid
arthritis
∗
0
50
100
150
200
P
l
a
s
m
a
 
l
e
v
e
l
s
 
o
f
 
I
L
-
2
1
 
(
p
g
/
m
L
)
(c)
0 0.1 0.2 0.3 0.4
Tfh cell (%)
I
L
-
2
1
 
(
p
g
/
m
L
)
r = 0.1383
P = 0.6095
0
500
1000
1500
(d)
Figure 3: Increased Bcl-6 mRNA, IL-21 mRNA expression, and plasma IL-21 concentration in RA patients. (a) Detection of Bcl-6 mRNA
expression in RA patients and healthy controls. Bcl-6 mRNA was estimated by real-time RT-PCR. Data correspond to the mean±SD of 7 RA
patients and 7 healthy controls (∗∗P<0.01). (b) Detection of IL-21 mRNA expression in RA patients and healthy controls. IL-21 mRNA was
estimated by real-time RT-PCR. Data correspond to the mean ± SD of 7 RA patients and 7 healthy controls (∗∗P<0.01). (c) Plasma IL-21
concentration in RA patients (n = 35) and healthy controls (n = 29) (∗P<0.05). (d) Relationship between plasma IL-21 concentration and
the frequency of circulating Tfh cells in RA patients (r =− 0.0320, P = 0.9100) (n = 15).
expression in CD4+ T cells of RA patients was higher than
that in control (1.90 ± 1.08 versus 5.24 ± 2.79, P<0.01)
(Figure 3(a)). IL-21 is derived from activated CD4+ Tc e l l s
including Tfh cells and could enhance B cells to produce
antibody. There was great increased IL-21 mRNA in CD4+ T
cells of RA patients compared with healthy controls (0.07 ±
0.08 versus 0.48 ± 0.54, P<0.01) (Figure 3(b)). At same
time, we found that the concentration of IL-21 in plasma
was signiﬁcant increased in RA patients (98.29 ± 8.40 versus
73.68 ± 7.28, P<0.05) (Figure 3(c)). Additionally, the IL-
21 concentrations did not vary with the frequency of the
circulating Tfh cells in RA patients (r =− 0.0321, P =
0.9100) (Figure 3(d)).
4. Discussion
Tfh cells are a class of regulatory T help cells that specialize
in the cognate control of antigen-speciﬁc B-cell immunity
[7], diﬀerent from other eﬀector T help cells in function.
Tfh cells express CXCR5, CXCR4, ICOS, PD-1, IL-21, and
other molecules [14–16]. Notably, highest amounts of ICOS
expressed in Tfh cells have a close correlation with the
capacity to support antibody production [17, 18]. It has
been reported that phenotype of CD4+CXCR5+ICOShigh
T cells resembles circulating Tfh cells and tonsillar Tfh
cells [11]. In this study, we have investigated the frequency
of the circulating Tfh cells in RA patients. The results6 Clinical and Developmental Immunology
demonstrate that the frequency of CD4+CXCR5+ICOShigh
TfhcellswasincreasedsigniﬁcantlyinRApatients,compared
with healthy controls. The percentage of CD4+ICOS+ cells
and CD4+ICOShigh cells in RA patients were also higher than
those in healthy controls. Our data provide ﬁrst evidence
that the circulating Tfh cells were increased in RA patients,
suggesting that Tfh cells may be involved in the pathogenesis
of RA.
It is known that Tfh cells are critical for directing the
development of an antibody response by GC B cell.The pres-
ence of autoantibody in the serum is a typical phenomenon
for RA patients. Rheumatoid factor (RF) was observed
originally by Franklin et al. in 1939 [19], which is present in
most inﬂammatory conditions. Anti-CCP antibody is very
speciﬁc for RA and has a sensitivity comparable to that of
RF [20–22]. We are interested in the relationship between
the circulating Tfh cells and autoantibodies in RA patients,
including anti-CCP antibody and RF. The results revealed
that the increased level of anti-CCP antibody correlated
positively with the frequency of circulating Tfh cells, but
changesinRFconcentrationsdidnotshowacorrelationwith
the frequency of circulating Tfh cells. Our data provide a
strong association between increased the circulating Tfh cells
and RA, which opens a new avenue in the study of RA. As
anti-CCP as a kind of representative autoantibody, is not
existed in all RA patients. According to the level of anti-
CCP antibody, RA patients were divided into two groups:
anti-CCP antibody-positive group and anti-CCP antibody-
negative group. The results showed that the frequency of
circulating Tfh cells in anti-CCP antibody-positive group
was higher than that in the anti-CCP antibody-negative
group. Taken together, these ﬁndings reveal that the produc-
tion of autoantibody in the RA patients is correlated with
the frequency of the circulating Tfh cells, which provide
evidence for the link between anti-CCP antibody and the
circulating Tfh cells and open a new avenue in the study of
RA.
Bryant et al. [23] have found that IL-21 induced the
secretionofvastquantitiesofIgM,IgG,andIgAbyallsubsets
of mature human B cells. Previous study has revealed that
IL-21 plasma levels were increased in patients with early
stage RA compared with controls [24]. We also detected
the concentration of plasma IL-21 and IL-21 mRNA in
PBMCs, the results showed that both the levels of IL-21 in
plasma and the IL-21 mRNA in CD4+ T cells of RA patients
were increased signiﬁcantly. Bcl-6 transcription factor is
selectively expressed by Tfh cells [14, 25]. The expression
of Bcl-6, regulated by IL-6 and IL-21, helps to distinguish
Tfh cells from other polarized T helper cell subsets [26].
Our data indicates that Bcl-6 mRNA markedly enhanced
when compared with healthy controls, which was measured
in CD4+ T cells of RA patients by RT-PCR.
In conclusion, our data provide evidence of increased
circulating Tfh cells in RA patients, suggesting that the
increase of the circulating Tfh cells may be associated with
the development of RA. However, it is critical to further
determinethemechanismsofcontrollingtheproductionand
activation of Tfh cells.
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